ArticleCureus2024
A Case of Pediatric Mixed Epithelial and Stromal Tumor of the Kidney With Atypical Stromal Cells.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mixed epithelial and stromal tumor of the kidney (MESTK) is a rare renal tumor characterized by both cystic and solid components. Although typically benign, its components can undergo malignant transformation, manifesting as a sarcomatous feature. Carcinomatous transformations are exceedingly rare. MESTK predominantly affects perimenopausal women, with male patients being rare and often associated with a history of hormonal therapy. Pediatric MESTK is extremely rare, with few reports. We herein report an eight-year-old child diagnosed with MESTK, exhibiting typical histological findings and featuring a few stromal cells with atypia in a focal area. These atypical cells exhibited bizarre nuclei and were positive for p53, although no mitotic figures were observed, and the Ki-67 labeling index was not elevated compared with the surrounding areas. The follow-up period was relatively short and there was no evidence of recurrence or metastasis. The patient remains under careful observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.